id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5739-0009,FDA,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry; Availability; Correction",Notice,Notice of Availability,2020-12-04T05:00:00Z,2020,12,2020-12-04T05:00:00Z,,2020-12-04T13:53:26Z,2020-26691,0,0,0900006484985c2a
FDA-2017-D-5739-0010,FDA,FDA-2017-D-5739,Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry,Other,Guidance,2020-12-04T05:00:00Z,2020,12,2020-12-04T05:00:00Z,,2020-12-04T14:05:26Z,,0,0,0900006484986175
FDA-2017-D-5739-0008,FDA,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry",Other,Guidance,2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2022-10-05T19:11:30Z,,0,0,09000064849761b3
FDA-2017-D-5739-0007,FDA,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry; Availability",Notice,Notice of Availability,2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2020-11-25T14:24:31Z,2020-26050,0,0,0900006484975d73